SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

TELO

Telomir Pharmaceuticals Inc.
NASDAQHealth Care

Latest close: 1.05 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record◆Adverse 8-K filing●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Oct 6, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Sep 17, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  3. Sep 16, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record1343 flagged findings
Reported transactions (Form 4)28since Feb 13, 2024 · and 15 other holdings
Corporate events (8-K)23since Feb 13, 2024

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 134)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 6, 268-K ↗Current report · Entered a material agreement
  • Sep 17, 268-K ↗Current report · Communication to the market
  • Sep 16, 268-K ↗Current report · Shareholder vote results
  • Sep 14, 268-K ↗Current report · Communication to the market
  • Aug 19, 26DEFA14A ↗Shareholder meeting and votes
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity · 5.2% · event on Jun 30, 26 · amendment
  • Aug 13, 2610-Q ↗Quarterly report
  • Aug 10, 268-K ↗Current report · Communication to the market
  • Jul 28, 26DEF 14A ↗Shareholder meeting and votes
  • Insider transaction · 3 Form 4 filingsshow all 3hide
  • Jun 15, 268-K ↗Current report · Communication to the market
  • Jun 9, 26Form 3 ↗Insider transaction
  • Jun 8, 268-K ↗Current report · A senior executive left or was appointed
  • Insider transaction · 4 Form 4 filingsshow all 4hide
  • May 20, 268-K ↗Current report · Communication to the market
  • May 14, 2610-Q ↗Quarterly report
  • Apr 30, 268-K ↗Current report · Other events
  • Apr 24, 26Form 4 ↗Insider transaction
  • Apr 24, 268-K ↗Current report · Entered a material agreement
  • Mar 31, 268-K ↗Current report · Other events

134 filings on record, the oldest from Sep 18, 23.

Listing the 25 most recent filings of the 134 on record.

8-Ks, explained

Stress1Structure13Governance9
  • Oct 6, 26StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Jun 8, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Apr 24, 26StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Mar 27, 26GovernanceA senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
  • Jan 12, 26StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Dec 22, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Nov 20, 25GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Oct 20, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • May 21, 25StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • May 21, 25StructureSold unregistered shares+1 more in the same filing8-K 3.02 ↗
  • Dec 20, 24GovernanceAuditor change filing (8-K Item 4.01)+1 more in the same filing8-K 4.01 ↗
  • Dec 11, 24StructureSold unregistered shares+1 more in the same filing8-K 3.02 ↗

5 older filings not shown

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity5.2%Jun 30, 26SCHEDULE 13G/A ↗2 earlier filings

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Aug 19, 24Sell$1KErez AminovCEO and Chairman↗
  • Aug 19, 24Sell$1KErez AminovCEO and Chairman↗
  • Feb 13, 24Buy$343KBay Shore Trust↗
  • Feb 13, 24Buy$280KBay Shore Trust↗
  • Feb 13, 24Buy$343KBay Shore Trust↗
Stock compensation, tax and giftsshow the other transactionhide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Apr 22, 26Other$10.0MErez AminovCEO and Chairman↗

The full record holds 6 transactions and goes back to Feb 8, 24.

Its sector and its market

Telomir Pharmaceuticals Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Telomir Pharmaceuticals Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Telomir Pharmaceuticals Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
134 documents on file, from Sep 18, 2023 to Oct 6, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.